Glaucoma News

Nearly half of patients with glaucoma-related mild central visual loss had defects in the far peripheral inferotemporal visual field, often in the form of temporal wedge or sector defects correlated with damage to the superior nasal optic disc nerve fiber bundles.

A multicenter, real-world, observational study showed safety and efficacy of a fixed-dose combination of preservative-free tafluprost and timolol in clinical practice. Patients who did not sufficiently respond to previous therapies achieved significant IOP reduction at 6 months, with the added benefit of decreased ocular surface side effects.

ORLANDO, Fla. – As patients learn more about alternative therapies, one glaucoma specialist still recommends medication first, then elevating low systemic blood pressure – and then supplements.

SAN FRANCISCO — Ensuring safe and effective products are available to the American people is the mission of the FDA Center for Drug Evaluation and Research, which is why there is a reason behind everything the FDA asks for when studying new drug products, according to a speaker at Glaucoma 360: New Horizons Forum.

ORLANDO — At Cataract Surgery: Telling It Like It Is, I. Paul Singh, MD, discusses how he has incorporated endoscopic cyclophotocoagulation in his practice in addition to MIGS procedures because ECP works to decrease inflow while most MIGS devices work to increase outflow.

SAN FRANCISCO — At Glaucoma 360: New Horizons Forum, Thomas A. Mitro, president and chief operating officer of Aerie Pharmaceuticals, updates the company’s progress with Rhopressa (netarsudil ophthalmic solution 0.02%) and Rocklatan (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution), and discusses receiving the Glaucoma Research Foundation’s Catalyst Award.

SAN FRANCISCO — At Glaucoma 360: New Horizons Forum, Thurein Htoo, MS, MBA, CEO of Qlaris Bio, discusses how the company is targeting episcleral venous pressure in the treatment of glaucoma. QLS-101, Qlaris Bio’s novel topical drug therapy, acts to reduce episcleral venous pressure, therefore reducing IOP.

Researchers in Wheaton, Ill., reported that patients with age-related macular degeneration were more likely to develop glaucoma and its risk factor, ocular hypertension, when treated repeatedly and frequently with anti-VEGF intravitreal injections.

SAN FRANCISCO — At the Glaucoma 360: New Horizons Forum, James C. Tsai, MD, MBA, president of New York Eye and Ear Infirmary of Mount Sinai and chair of the department of ophthalmology at Icahn School of Medicine at Mount Sinai, discusses neuroprotection technology from ReNetX Bio for glaucoma. The new biologic protein enhances regeneration of dead or damaged retinal ganglion cells, he said.

SAN FRANCISCO — At the Glaucoma 360: New Horizons Forum, Jeffrey L. Goldberg, MD, PhD, professor and chair of ophthalmology at Byers Eye Institute at Stanford University, discusses phase 2 data regarding an implant from Neurotech that releases ciliary neurotrophic factor.